JK

Jitin Katara

Active Director Director DIN 11523079
DIN 11523079 First appointment Feb 2026 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Jitin Katara

Data last updated:

Jitin Katara is a Director at Adinoseen Pharmaceuticals Private Limited (since 2026). The company operates in Healthcare.

DIN 11523079
Primary Designation Director
Industry Healthcare
First Appointment 04 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Feb 20262026Active

Board colleagues of Jitin Katara

NameDINCompanyDesignation
Omprakash11523080Adinoseen Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Adinoseen Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jitin Katara

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jitin Katara

Jitin Katara currently holds 1 directorship: Adinoseen Pharmaceuticals Private Limited (Director, since 04 Feb 2026).

Jitin Katara was first appointed on 04 Feb 2026 as Director at Adinoseen Pharmaceuticals Private Limited.

The current boards of Jitin Katara's companies include Omprakash (Adinoseen Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available